Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab

Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Nishan H. Fernando, Herbert I. Hurwitz Oncologist 2003; 9(Suppl 1): 11-18 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in immunotherapy, monoclonals, and vaccines and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the clinical experience of bevacizumab in colorectal cancer. Explain the relevant biology and preclinical drug development of bevacizumab in colorectal cancer. Discuss future directions of research. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: June 3, 2004 Most Recent Review: June 3, 2004* Most Recent Update: June 3, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Targeting VEGF in Cancer Treatment.